Journal
JOURNAL OF IMMUNOLOGY
Volume 194, Issue 3, Pages 855-860Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1402513
Keywords
-
Categories
Funding
- National Institutes of Health [R01 HL096376, R01 HL097376, R01 HL098174, R01 HL081784, 1UH2HL123502, P01 HL114453]
- U.S. Department of Veterans Affairs
Ask authors/readers for more resources
The acute respiratory distress syndrome (ARDS) is a form of severe hypoxemic respiratory failure that is characterized by inflammatory injury to the alveolar capillary barrier, with extravasation of protein-rich edema fluid into the airspace. Although many modalities to treat ARDS have been investigated over the past several decades, supportive therapies remain the mainstay of treatment. In this article, we briefly review the definition, epidemiology, and pathophysiology of ARDS and present emerging aspects of ARDS pathophysiology that encompass modulators of the innate immune response, damage signals, and aberrant proteolysis that may serve as a foundation for future therapeutic targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available